Cuba have developed, patented and officially registered the world’s first lung cancer vaccine. The CIMAVAX-EGF vaccine became the fruit of 15 year-long labor of Havana Molecular Immunology Center (Centro de Inmunología Molecular).

Hundreds of oncology patients have already passed this truly unique medication treatment course.
Makers of the Cuban vaccine claim that this unique medication allows turning the advanced stages of lung cancer into a “controlled chronic disease”.
CIMAVAX-EGF effect is not a direct attack on the tumor itself, but prevention of its sustenance in a manner that causes the lung cancer to “die of hunger”.

“Vaccine is developed on the basis of protein, common for all people: epidermal growth factor, related to cellular proliferation which grows out of control in case of cancer”

CIMAVAX-EGF – therapeutic vaccine for lung cancer treatment. CIMAVAX-EGF is a Cuban lung cancer treatment medicine, developed by Havana Molecular Immunology Center (MIC) was registered by the Ministry of Health Care and is used since 2008.

Dr. Augustin Lage Davila, MIC Director General said: “Biotechnology is a key to transforming the cancer from a lethal disease into a chronic one. ”.